China Glp-1 Receptor Agonist Market Size & Outlook
China glp-1 receptor agonist market, 2018-2030 (US$M)
Related Markets
China glp-1 receptor agonist market highlights
- The China glp-1 receptor agonist market generated a revenue of USD 988.3 million in 2023 and is expected to reach USD 4,778.4 million by 2030.
- The China market is expected to grow at a CAGR of 25.2% from 2024 to 2030.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2023.
- Other Products is the most lucrative product segment registering the fastest growth during the forecast period.
Glp-1 receptor agonist market data book summary
| Market revenue in 2023 | USD 988.3 million |
| Market revenue in 2030 | USD 4,778.4 million |
| Growth rate | 25.2% (CAGR from 2023 to 2030) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Other Products |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Trulicity, Rybelsus (oral semaglutide), Saxenda, Victoza (liraglutide), Other Products |
Other key industry trends
- In terms of revenue, China accounted for 2.7% of the global glp-1 receptor agonist market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China glp-1 receptor agonist market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 578.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China glp-1 receptor agonist market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glp-1 receptor agonist market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 70.82% in 2023. Horizon Databook has segmented the China glp-1 receptor agonist market based on ozempic (semaglutide), trulicity, rybelsus (oral semaglutide), saxenda, victoza (liraglutide), other products covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the major pharmaceutical markets in the Asia Pacific region, and its growth is driven by the local presence of a large number of drug manufacturers, favorable government initiatives, and a high target disease burden due to its large population.
The rising rates of diabetes and obesity in China represent a significant public health challenge. With diabetes impacting over 12% of adults and projected obesity rate increases, there is an urgent demand for comprehensive public health strategies.
The growing prevalence propels the need to implement initiatives that promote healthier lifestyle, raise awareness, and expand treatment options. These efforts are critical in managing the growing diabetes and obesity epidemic in China.
Reasons to subscribe to China glp-1 receptor agonist market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China glp-1 receptor agonist market databook
-
Our clientele includes a mix of glp-1 receptor agonist market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China glp-1 receptor agonist market , including forecasts for subscribers. This country databook contains high-level insights into China glp-1 receptor agonist market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China glp-1 receptor agonist market size, by product, 2018-2030 (US$M)
China GLP-1 Receptor Agonist Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
